Indegene IPO: GMP, Reviews, Details & Analysis (Should You Buy?)

Considering the Indegene IPO? Explore GMP, expert reviews, key details, listing date, and share price to make informed investment decisions.

Indegene Limited, a commercialization service provider to the life sciences industry, is all set to make its debut in the stock market. The company’s initial public offering (IPO) is scheduled to open on May 6, 2024, and it will close on May 8, 2024. Let’s dive into the details of this exciting IPO:

Key Facts and Figures:

Issue Size: The Indegene IPO is a book-built issue with a total size of Rs 1,841.76 crores. It comprises a fresh issue of 1.68 crore shares (aggregating to Rs 760.00 crores) and an offer for sale of 2.39 crore shares (aggregating to Rs 1,081.76 crores).

Price Band: The price band for the IPO is set at ₹430 to ₹452 per share.
Minimum Lot Size: Retail investors can apply for a minimum of 33 shares.

Listing Date: The tentative listing date for Indegene IPO is Monday, May 13, 2024.
Who Can Invest?

Retail Investors: The minimum investment required by retail investors is ₹14,916.
NII (HNI) Investors: NII investors can bid for a minimum of 14 lots (462 shares), amounting to ₹208,824.

bNII Investors: bNII investors can bid for a minimum of 68 lots (2,244 shares), amounting to ₹1,014,288.

Book Running Lead Managers and Registrar:
The book running lead managers for the Indegene IPO are Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory And Securities (India) Pvt Ltd.
The registrar for her issue is Link Intime India Private Ltd.

Anchor Investors:

Indegene IPO raised Rs 548.78 crore from anchor investors.
The anchor bid date was May 3, 2024.
Anchor lock-in period end date for 50% shares is June 8, 2024, and for the remaining shares, it’s August 7, 2024.

Investment Considerations:

While Indegene’s unique positioning and financial growth make it an attractive investment opportunity, investors should also consider the high valuation and client concentration risk associated with the company.

In summary, the Indegene IPO presents a mix of opportunities and risks. As the subscription window opens, investors will closely watch the response from the market. Stay tuned for further updates!

Leave a Comment